...
首页> 外文期刊>CNS neuroscience & therapeutics >Synergistic mechanism of gene expression and pathways between jasminoidin and ursodeoxycholic acid in treating focal cerebral ischemia-reperfusion injury
【24h】

Synergistic mechanism of gene expression and pathways between jasminoidin and ursodeoxycholic acid in treating focal cerebral ischemia-reperfusion injury

机译:茉莉素与熊去氧胆酸之间基因表达及途径的协同作用机制

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Jasminoidin and ursodeoxycholic acid are 2 bioactive compounds extracted from Chinese medicine that have been proven to exert a synergistic effect as a combined administration for the treatment of stroke. The aim of this study was to reveal the pharmacogenomic mechanism of this synergistic effect of jasminoidin and ursodeoxycholic acid. Methods: One hundred and fifteen mice with brain damage, induced by focal cerebral ischemia/reperfusion, were divided into 5 groups: jasminoidin-treated, ursodeoxycholic acid-treated, combination-treated, vehicle group, and sham-operated group. Comparative analysis of stroke-related gene expression profiles and Kyoto Encyclopedia of Genes and Genomes pathways among the 3 treatment groups were performed to reveal the mechanism of this synergistic effect. Results: This study demonstrated that (1) treatment with jasminoidin alone caused similar changes in the pattern of gene expression as those treated with the combination; (2) jasminoidin treatment and the combination treatment had more overlapping changes in gene expression and activated pathways than the ursodeoxycholic acid treatment; (3) Hspa1a and Ppm1e were only up-regulated in the combination-treated group; (4) the nonoverlapping genes Fgf12, Rarα, Map3k4, paxillin (PXN) in the combination-treated group were markedly expressed, and P53 pathway was obviously activated in the combination-treated group. Conclusion: These findings may suggest that jasminoidin is the major component of the combination, and the combination plays an important role of the synergistic effect in up-regulating expression of gene Hspa1a, genes Fgf12, Rarα, Map3k4 and down-regulating gene PXN, as well as activating P53 pathway.
机译:目的:茉莉素和熊去氧胆酸是从中药中提取的两种生物活性化合物,已被证明具有联合治疗中风的协同作用。这项研究的目的是揭示茉莉素和熊去氧胆酸协同作用的药物基因组学机理。方法:将115只因局灶性脑缺血/再灌注所致脑损伤的小鼠分为5组:茉莉素治疗组,熊去氧胆酸治疗,联合治疗,赋形剂组和假手术组。比较了三个治疗组中风相关基因的表达谱和《京都议定书》的基因与基因组途径,以揭示这种协同效应的机制。结果:这项研究表明(1)单独使用茉莉素治疗与联合治疗相比,基因表达模式发生了相似的变化; (2)与熊去氧胆酸治疗相比,茉莉素和联合治疗在基因表达和激活途径上有更多的重叠变化; (3)Hspa1a和Ppm1e仅在联合治疗组上调; (4)在联合治疗组中明显表达了非重叠基因Fgf12,Rarα,Map3k4,paxillin(PXN),并且在联合治疗组中明显激活了P53途径。结论:这些发现可能表明茉莉素是该组合的主要成分,并且该组合在上调基因Hspa1a,基因Fgf12,Rarα,Map3k4和下调基因PXN的表达中起着协同作用。以及激活P53途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号